News
NUVB-WS
0.0051
+24.39%
0.0010
Weekly Report: what happened at NUVB last week (0406-0410)?
Weekly Report · 2d ago
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
The Motley Fool · 2d ago
How Investors May Respond To Nuvation Bio (NUVB) EMA Review Of Taletrectinib Milestone Opportunity
Simply Wall St · 5d ago
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB)
TipRanks · 04/08 11:31
RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)
TipRanks · 04/08 01:50
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)
TipRanks · 04/06 20:40
Weekly Report: what happened at NUVB last week (0330-0403)?
Weekly Report · 04/06 09:42
A Look At Nuvation Bio (NUVB) Valuation As EMA Validates Taletrectinib Marketing Application
Simply Wall St · 04/06 08:19
Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?
Simply Wall St · 04/03 19:24
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
PR Newswire · 04/02 17:19
Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush
Dow Jones · 04/02 13:13
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Nuvation Bio (NUVB) and Argenx Se (ARGX)
TipRanks · 04/02 12:20
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/02 11:40
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo
Seeking Alpha · 04/01 13:01
Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo
TipRanks · 04/01 12:16
Nuvation Bio Acquires Japan Rights For Safusidenib; Now Owns Global Clinical Development Program
NASDAQ · 04/01 12:14
Nuvation Bio Amends Current License Deal With Daiichi Sankyo For Safusidenib To Add Japan Rights
Benzinga · 04/01 12:07
*Nuvation Bio Now Has Global Development and Commercialization Rights for Safusidenib >NUVB
Dow Jones · 04/01 12:01
*Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib From Daiichi Sankyo
Dow Jones · 04/01 12:01
*Nuvation Bio: Agreement Provides Ownership of Global Clinical Development Program, Inclusive of Clinical Trials, Past and Current Data Generation, and Future Publications >NUVB
Dow Jones · 04/01 12:01
More
Webull provides a variety of real-time NUVB-WS stock news. You can receive the latest news about Nuvation Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About NUVB-WS
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.